Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Spero pivots to I&I with $1.1B deal for Innovent antibody, sells slice of Utebzi royalties for $105M

Spero pivots to I&I with $1.1B deal for Innovent antibody, sells slice of Utebzi royalties for $105M

  • July 13, 2026

Spero Therapeutics is pivoting to immune and inflammation indications through a license agreement for a CD40L antibody with Innovent Biologics in a deal worth up to $1.1 billion.

Leave A Comment

Fields (*) Mark are Required